Cosmetic Use of AbobotulinumtoxinA in Men: Considerations Regarding Anatomical Differences and Product Characteristics.
The proportion of men seeking facial rejuvenation with botulinum neurotoxin type A (BoNTA) products is increasing. The number of male patients treated in the 5-year period between 2009 and 2014 grew by 25%. There is little clinical data supporting gender-specific efficacy with regard to dosing and injection placement in men. To nurture the confidence associated with treatment of male patients, clinicians are in need of more informational materials to develop their evaluation and treatment strategies. Three BoNTA products are currently available in the United States (US) for treatment of the upper face. The varying potency of the different BoNTA formulations is reflected by disparate dose-response characteristics, meaning they are not interchangeable for injection purposes. Clinicians who are familiar with the characteristics of all the BoNTA options will be equipped with the necessary tools to provide their male patients with a desired outcome.<br /> Among the product options available in the US, Dysport&reg;(abobotulinumtoxinA) (Galderma Laboratories, L.P., Fort Worth, Texas) is unique in that its recommendations for reconstitution provide the clinician with 2 different final product concentrations. The flexibility provided by a variable dose may be a valuable tool for tailoring treatments to male patient-specific needs, which may include a more conservative outcome, maintaining a certain degree of muscle activity and expressivity. Achieving a conservative outcome may be the key to a positive experience for the male patient. <br /><br /> <em>J Drugs Dermatol.</em> 2016;15(9):1056-1062.
Jason D
JD
Bloom
Jeremy B
JB
Green
Whitney
W
Bowe
Erika
E
von Grote
Alessandra
A
Nogueira
D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000737:chemistry; D002986:Clinical Trials as Topic / Q000379:methods; D003357:Cosmetic Techniques; D003358:Cosmetics / Q000008:administration & dosage* / Q000737:chemistry; D004339:Drug Compounding; D005145:Face / Q000033:anatomy & histology*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D012060:Rejuvenation; D012727:Sex Characteristics; D015595:Skin Aging / Q000187:drug effects* / Q000473:pathology
D003358:Cosmetics; D019274:Botulinum Toxins, Type A; C542869:abobotulinumtoxinA